- /
- Supported exchanges
- / F
- / 29A.F
Amphastar P (29A F) stock market data APIs
Amphastar P Financial Data Overview
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Amphastar P data using free add-ons & libraries
Get Amphastar P Fundamental Data
Amphastar P Fundamental data includes:
- Net Revenue: 720 M
- EBITDA: 220 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-26
- EPS/Forecast: 0.92
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amphastar P News
New
Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Pharma Stock to Buy for Long Term Growth?
We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) stands against ot...
2 Reasons to Like AMPH and 1 to Stay Skeptical
2 Reasons to Like AMPH and 1 to Stay Skeptical What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. Th...
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Amphastar Pharmaceuticals (NASDAQ:AMPH) has had a rough three months with its share price down 35%. However, a closer look at its sound financials might cause you to think again. Given that fundamenta...
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be parti...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.